IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia.
Jonathan D PaolinoHarrison K TsaiMarian H HarrisYana PikmanPublished in: Biomedicines (2024)
IKZF1 encodes the transcription factor IKAROS, a zinc finger DNA-binding protein with a key role in lymphoid lineage development. IKAROS plays a critical role in the development of lineage-restricted mature lymphocytes. Deletions within IKZF1 in B-cell acute lymphoblastic leukemia (B-ALL) lead to a loss of normal IKAROS function, conferring leukemic stem cell properties, including self-renewal and subsequent uncontrolled growth. IKZF1 deletions are associated with treatment resistance and inferior outcomes. Early identification of IKZF1 deletions in B-ALL may inform the intensification of therapy and other potential treatment strategies to improve outcomes in this high-risk leukemia.
Keyphrases
- acute lymphoblastic leukemia
- allogeneic hematopoietic stem cell transplantation
- stem cells
- transcription factor
- binding protein
- acute myeloid leukemia
- single cell
- bone marrow
- single molecule
- circulating tumor
- type diabetes
- risk assessment
- metabolic syndrome
- adipose tissue
- drug delivery
- skeletal muscle
- bioinformatics analysis